Background-Neutrophils (PMNs) are known to contribute to both cardiac dysfunction and myocardial necrosis after reperfusion of an ischemic heart. Moreover, platelets are also important blood cells that can aggravate myocardial ischemic injury. This study was designed to test the effects of PMNs and platelets separately and together in provoking cardiac dysfunction in isolated perfused rat hearts after ischemia and reperfusion. Methods and Results-Control rat hearts not subjected to ischemia were perfused without blood cells for 80 minutes.
R eperfusion of the ischemic myocardium often results in neutrophil (PMN)-induced myocardial injury as well as in cardiac contractile dysfunction. [1] [2] [3] PMNs accumulate in the microvasculature, which can lead to microvascular plugging, resulting in impaired coronary perfusion. 4, 5 Postreperfusion cardiac necrosis and cardiac contractile dysfunction can be prevented by depletion of circulating leukocytes 6 or by monoclonal antibodies and ligand blockers directed against cell adhesion molecules. [7] [8] [9] More recently, exogenous administration of physiological levels of a nitric oxide donor 10, 11 has been found to markedly attenuate the cardiac dysfunction induced by PMNs in perfused rat hearts subjected to ischemia and reperfusion. In these isolated perfused rat heart studies, PMNs were added to plasma, and this mixture was added to the Krebs-Henseleit perfusion fluid. 10, 11 However, there were no platelets in the cardiac perfusate in these experiments.
Platelets are a known source of a variety of inflammatory mediators, including thromboxane A 2 , 12 P-selectin, 13 and platelet factor 4, 14 all of which upregulate either the complement system or a variety of cytokines. 14, 15 PMNs also release a variety of cell-activating and cytotoxic mediators, including cytokines (ie, tumor necrosis factor-␣, interleukin-1␤), complement products (eg, C5a [6] [7] [8] [9] ), proteolytic enzymes (eg, elastase, cathepsin G), and oxygen-derived free radicals (eg, superoxide) that may contribute to platelet activation. 16 -18 However, little is known regarding cross-talk between PMNs and platelets in contributing to the pathophysiology of myocardial ischemia and related cardiovascular disease states. Recently, Neumann et al 15 showed that leukocyte-platelet binding is increased in patients with acute myocardial infarction as well as in patients with unstable angina. 19 More recently, others have shown that platelets and PMNs interact in regulating vascular tone in arteries injured by angioplasty. 20 Nevertheless, the nature of the interaction between platelets and PMNs is not known with regard to their influence on cardiac performance in myocardial ischemia/ reperfusion injury or how these 2 blood cell types communicate with the vasculature.
The major purpose of this study was to investigate the effect of platelets and PMNs separately and together on cardiac performance in a well-controlled, established model of ischemia/reperfusion in the isolated perfused rat heart and to assess the role of the selectin family of glycoprotein adhesion molecules in modulating cardiac dysfunction in blood cell-perfused rat hearts subjected to myocardial ischemia/reperfusion.
Methods

Isolated Rat Heart Experiments
Male Sprague-Dawley rats (250 to 300 g) were anesthetized with 40 mg/kg sodium pentobarbital and given 1000 U sodium heparin IP (Abbott Laboratories, Diagnostic Division). After a midline thoracotomy, the hearts were rapidly excised, the ascending aorta was cannulated, and retrograde perfusion of the heart was initiated on a Langendorff apparatus at a constant pressure of 80 mm Hg. These isolated hearts were perfused with a Krebs bicarbonate buffer of the following composition (in mmol/L): glucose 17, NaCl 120, NaHCO 3 25, CaCl 2 2.5, EDTA 0.5, KCl 5.9, and MgCl 2 1.2, maintained at 37°C. The perfusate was oxygenated with 95% O 2 /5% CO 2 , which equilibrated at a pH of 7.3 to 7.4. Two sidearms in the perfusion line located just proximal to the heart inflow cannula allowed infusion of PMNs, platelets, and plasma directly into the coronary inflow line. To assess cardiac contractile function, a 2.5F microtip catheter transducer (Millar Instruments, Inc) was inserted directly into the left ventricular cavity as previously reported. 10, 11 Left ventricular pressures, maximal rate of development of left ventricular pressure (ϩdP/dt max ), coronary flow, and heart rate were all recorded with a MacLab data acquisition system (ADI Diagnostics Inc) in conjunction with a Power Macintosh 7600 computer (Apple Computers). All data were stored and analyzed at the end of each experiment.
Rat Neutrophil Isolation
Neutrophil donor rats (300 to 350 g) received a 10-mL injection of 0.5% glycogen IP (Sigma Chemical Co). Eighteen hours later, the rats were anesthetized with ethyl ether, and the neutrophils were harvested by peritoneal lavage in PBS. The peritoneal lavage was centrifuged at 3000 rpm and 4°C for 10 minutes as previously described. 11 Finally, the PMNs were washed in Krebs buffer and counted with a microscope and hemocytometer. These neutrophil preparations were Ͼ95% pure and Ͼ95% viable according to exclusion of 0.3% trypan blue as the criterion for viability. Furthermore, PMNs obtained by this method have been found to respond normally in cell adhesion tests.
11
Additional neutrophils were isolated from blood according to the method of Williams et al 21 using the hetastarch exchange transfusion technique in 400-g rats anesthetized with pentobarbital sodium 40 mg/kg IP. Yields of 120ϫ10 6 PMNs per rat were obtained, which were Ͼ95% pure and Ͼ95% viable by the trypan blue exclusion test. These blood PMNs were washed 5 to 6 times with PBS to remove the hetastarch before use.
Rat Platelets and Plasma
Whole blood was obtained by an intracardiac puncture in anesthetized rats with a 20-mL plastic syringe with a 20-gauge needle (Becton Dickinson) containing 2000 U sodium heparin. To obtain platelets, the whole blood was immediately spun in a refrigerated centrifuge (GSGR; Beckman Instruments, Inc) at 900 rpm for 10 minutes. The supernatant was collected and centrifuged again at 3000 rpm for 10 minutes, and the plasma was decanted from the platelets. Next, the platelets were resuspended in Krebs buffer and counted. Platelet preparations were Ͼ95% pure.
Perfused Heart Experimental Protocol
After a 15-minute stabilization period, baseline left ventricular developed pressure (LVDP), ϩdP/dt max , and coronary flow were measured every 5 minutes for 15 minutes to ensure complete equilibration of the hearts. Flow of Krebs buffer was then reduced to zero, creating global, total ischemia. This ischemia was maintained for 20 minutes. Reperfusion of the hearts was instituted by restoration of flow of buffer to the heart to that of preischemic levels. At 5 minutes of reperfusion, either 75ϫ10 6 PMNs alone, 100ϫ10 6 platelets alone, or both cell types together were infused into the hearts. In a separate series of 5 rat hearts, 75ϫ10 6 PMNs plus 750ϫ10 6 platelets were infused together in rat hearts subjected to the same ischemia-reperfusion protocol. A few additional hearts were perfused with either 100ϫ10 6 PMNs or 50ϫ10 6 platelets. The blood cells were infused over a 5-minute period directly into the coronary circulation via a set of side ports situated in the perfusion line just proximal to the inflow cannula. The PMNs were suspended in 5.0 mL of Krebs buffer in a 5.0-mL syringe, and the platelets were suspended in 5.0 mL of plasma and also placed in a separate 5.0-mL syringe located just distal to the platelet inflow port and just proximal to the inflow port to the coronary circulation. The hearts were allowed to reperfuse for a total of 45 minutes, during which time data were collected every 5 minutes for the first 30 minutes and at the 45-minute time point. A sialyl Lewis X -oligosaccharide (SLe X -OS) (CY-1503) was obtained from Cytel, Inc and diluted in Krebs buffer. 9 In additional experiments, we used a soluble P-selectin ligand (sPSGL-1) described by Takada et al 22 that acts as a specific P-selectin inhibitor. Appropriate amounts of this antiselectin agent were infused over the first 5 minutes of reperfusion. Finally, we perfused 5 rat hearts with 100ϫ10 6 PMNs alone isolated from blood, as described above.
Determination of Cardiac Tissue Myeloperoxidase
Myocardial tissue myeloperoxidase (MPO), an enzyme that occurs virtually exclusively in neutrophils, was determined as described previously. 23 One unit of MPO is defined as that quantity of enzyme that hydrolyzes 1 mmol peroxide per minute at 25°C. The assays were performed without knowledge of the group in which each sample originated.
Histology and Immunohistochemistry
In addition to the hearts used for assessment of left ventricular function, other rat hearts were perfused to determine the number of PMNs infiltrating into the heart by histological methods. After 45 minutes of reperfusion, hearts were removed from the perfusion apparatus and placed in 4% paraformaldehyde overnight at 4°C. The heart was cut into sections and dehydrated in graded acetone washes at 4°C. Tissue sections were embedded in plastic (Immunobed; Polysciences Inc), and 4-m-thick sections were cut and transferred to Vectabond-coated slides (Vector Laboratories, Inc). The slides were soaked in 95% ethanol for 10 minutes to remove some of the plastic embedding material and to allow staining of the tissue. After the 10-minute ethanol wash, the tissue sections were stained with either hematoxylin solution, Gill No. 3 (Sigma) for 10 minutes or Giemsa stain (Sigma) for 3 minutes. The slides were then observed microscopically, and the numbers of PMNs and platelets were counted and tallied. Five fields from each of 2 slides were counted from each heart, and 3 rats were studied in each group.
Immunohistochemistry for P-selectin was performed on tissue sections according to previously described techniques in 3 to 4 hearts from each group. 11 The basic method used was the avidin-biotin immunoperoxidase technique with monoclonal antibody PB1.3 as the monoclonal antibody directed against P-selectin. Positive staining was defined as a coronary microvessel displaying brown reaction product on Ͼ50% of the circumference of its endothelium. Fifty vessels per tissue sample were examined in each of 3 or 4 hearts per group.
Statistical Analysis
All data are presented as meanϮSEM. Data were compared by ANOVA using post hoc analysis with Fisher's corrected t test. The data on coronary flow and left ventricular function were analyzed by ANOVA incorporating repeated measures. A probability value of 0.05 was considered statistically significant.
Results
Perfusion of rat hearts at control flows for 80 minutes or perfusion of rat hearts for 15 minutes at control flow followed by 20 minutes of global ischemia and 45 minutes of reperfusion at control flows in the absence of either PMNs or platelets resulted in a completely normal coronary flow, LVDP, and dP/dt max at the end of the 80-minute observation period. Moreover, perfusion of control nonischemic hearts without blood cells, with PMNs alone, with platelets alone, or with both PMNs and platelets did not alter any index of cardiac function measured. Thus, this perfused rat heart model subjected to ischemia/reperfusion does not result acutely in either a flow deficit or a cardiac dysfunction in the absence of blood cells. Conversely, perfusion of hearts with blood cells in the absence of ischemia/reperfusion also exerted no coronary flow deficit or cardiac dysfunction. However, ischemic hearts reperfused in the presence of PMNs or platelets exhibited modest but significant adverse cardiodynamic effects (ie, reduced coronary flow, cardiac dysfunction). When elicited rat PMNs isolated by peritoneal lavage were compared with rat PMNs isolated from blood, the blood PMNs exerted a slightly greater cardiac dysfunction than the elicited PMNs. Thus, the final LVDP was 40Ϯ5 mm Hg in the presence of 100ϫ10 6 elicited PMNs and 36Ϯ3 for 5 hearts in the presence of 100ϫ10 6 freshly isolated PMNs. Similarly, comparable values were obtained for dP/dt max and coronary flow. Moreover, reperfusion of ischemic hearts with both PMNs and platelets produced profound deficits in coronary flow and a dramatic degree of cardiac dysfunction. When 75ϫ10 6 PMNs were coperfused with 750ϫ10 6 platelets, the final LVDP was 38Ϯ4 mm Hg, compared with 40Ϯ5 mm Hg when only 100ϫ10 6 platelets were used. These results are not significantly different, suggesting that the ratio of platelets to PMNs is not critical. Ischemic/reperfused (I/R) hearts perfused with PMNs or platelets alone exhibited significant effects. Coronary flow returned to 90Ϯ1% of control in the presence of 75ϫ10 6 PMNs and to 93Ϯ1% of control in the presence of 100ϫ10 6 platelets (PϽ0.05 from initial values in both cases) ( Figure  1 ). However, when these same numbers of PMNs and platelets were coperfused in I/R hearts, coronary flow returned to only 54Ϯ7% of control, a value significantly lower than in any other group (PϽ0.001 from initial). This proischemic effect represents a synergistic relationship between platelets and neutrophils, because their effects are 3 times greater than the additive effects of platelets and PMNs given alone (Figure 1) . Nevertheless, perfusion under these conditions with a SLe X -OS, a selectin-blocking agent, prevented these effects on coronary flow. Similarly, perfusion with sPSGL-1 at 5 g/mL resulted in a decrease in coronary flow of only 5Ϯ3%, a value not significantly different from that of the SLe X -OS-treated hearts. Similar results were obtained with regard to left ventricular cardiodynamics (ie, LVDP, Figure 2) . LVDP decreased by 10Ϯ2% in hearts perfused with PMNs and 11Ϯ2% in hearts perfused with platelets (PϽ0.05 from initial) (Figure 2 ). However, perfusion with both PMNs and platelets resulted in a decline in LVDP of 54Ϯ3% (PϽ0.001 from initial and from all other groups), again indicating a marked degree of synergy between PMNs and platelets. Moreover, addition of SLe X -OS to the perfusate containing both PMNs and platelets completely blocked this cardiac dysfunction exemplified by the decline in LVDP (Figure 2 ). In 5 additional rat hearts perfused with sPSGL-1 at 5 g/mL, the decline in LVDP was only 2Ϯ2%.
As would be expected, the first derivative of LVDP (ie, dP/dt max ) exhibited the same relationships as did the basic LVDP data (Figure 3) . Thus, coronary perfusion with PMNs or with platelets resulted in decreases in dP/dt max of 5Ϯ3% and 4Ϯ3% (ie, not significantly different from initial), whereas the combination of platelets and PMNs resulted in a reduction in dP/dt max of 55Ϯ4% (PϽ0.001 from initial or any other group), reinforcing the dramatic degree of synergy between PMNs and platelets in inducing cardiac dysfunction. Perfusion with the antiselectin agent (ie, SLe X -OS) in combination with platelets and PMNs attenuated the decrease in dP/dt max to 12Ϯ5% (PϽ0.001 from I/RϩPMNsϩplatelet) ( Figure 3 ). In 5 additional rat hearts perfused with sPSGL-1 at 5 g/mL, the decrease in dP/dt max was only 6Ϯ4%.
We also collected the hearts at the end of the reperfusion period, froze them at Ϫ70°C, and analyzed cardiac tissue for MPO activity as an index of accumulated PMNs. No MPO activity could be detected in control hearts or any I/R heart not perfused with PMNs, thus indicating that there are very few resident PMNs in the perfused rat hearts. However, Figure 4 shows that perfusion of I/R hearts with 75ϫ10 6 PMNs increased MPO activity significantly (PϽ0.05 from ischemia/reperfusion alone). Furthermore, coperfusion of I/R hearts with PMNs and platelets increased the MPO activity 3-fold (PϽ0.02 from I/RϩPMNs). However, addition of SLe X -OS to the PMNs and platelets perfusing I/R hearts dramatically attenuated MPO activity to values below those observed for I/RϩPMNs alone ( Figure 4) . As an additional verification of the MPO activity, we performed histological analysis of perfused rat hearts and counted PMNs and platelets in these sections. Figure 5 summarizes these results. Essentially no resident leukocytes were observed in perfused rat hearts subjected to ischemiareperfusion under the conditions of the current protocol. However, when the hearts were perfused with 75ϫ10 6 PMNs, Ͼ100 PMNs could be detected per field on each section. The percentage of intravascular PMNs was 83%. No extravascular platelets were observed. Perfusion with 75ϫ10 6 PMNs and 100ϫ10 6 platelets resulted in significantly greater numbers of both PMNs and platelets on each microscopic field (PϽ0.001), indicating a synergistic interaction between the 2 blood cell types. Moreover, coinfusion of the SLe X -OS along with the platelets and PMNs essentially abolished accumulation of both cell types (PϽ0.001 from I/RϩPMNsϩplate-lets). Similar results were obtained with the sPSGL-1-perfused hearts. The MPO activity was 0.08Ϯ0.01 U/g heart Figure 2 . Initial and final LVDP expressed in mm Hg in isolated perfused rat hearts subjected to 20 minutes of global total ischemia and reperfusion. Ischemic hearts were reperfused in the presence (PMNs, 75ϫ10 6 and platelets, 100ϫ10 6 ) or absence of PMNs and/or platelets (Plats). PMNs markedly decreased recovery of hearts throughout reperfusion, which was facilitated by platelets. All values are expressed as meanϮSEM. Numbers of hearts are at bottom of bars. *PϽ0.05, ***PϽ0.001. wt, a value not significantly different from that obtained with SLe X -OS. Figure 6 illustrates the degree of expression of P-selectin on coronary venules in perfused rat hearts. No P-selectin expression was observed in any nonischemic perfused rat hearts. Moreover, very low expression was observed in I/R rat hearts perfused without blood cells (ie, 1% of the vessels). The presence of 75ϫ10 6 PMNs or 50ϫ10 6 platelets increased P-selectin expression modestly, but perfusion with both PMNs and platelets resulted in a marked increase in P-selectin expression on the coronary vascular endothelium (PϽ0.01). This enhanced expression of P-selectin was markedly attenuated by coperfusion with the SLe X -OS, the antiselectin agent (PϽ0.001). One can therefore conclude that P-selectin upregulation on the I/R coronary vascular endothelium occurs in the presence of platelets and neutrophils and that this is attenuated by SLe X -OS, which inhibits selectin-mediated interaction between platelets and PMNs, platelets and the endothelium, and PMNs and the endothelium.
Discussion
The results obtained in this study clearly point toward 2 important conclusions. First, circulating neutrophils at the time of reperfusion contribute significantly to postreperfusion cardiac contractile dysfunction. Second, blood platelets act in a cooperative manner, synergizing with PMNs to exacerbate this cardiac contractile dysfunction. Although we believe that this is the first report of synergism between platelets and neutrophils in promoting postreperfusion cardiac dysfunction, other reports suggesting PMN-platelet interaction in patients with coronary artery disease have recently appeared. 15, 19 In this regard, leukocyte-platelet binding has recently been shown to occur in patients either with unstable angina 19 or after acute myocardial infarction. 15 The basis for this cell-tocell interaction is not known but may involve P-selectin upregulation on platelet or endothelial cell membranes. 24 This concept is consistent with the finding that thrombin stimulation of platelets leads to increased expression of proinflammatory cytokines (eg, interleukin-1␤ and interleukin-8) by leukocytes. 15 Thus, P-selectin may mediate plateletneutrophil interaction after ischemia-reperfusion, such as that observed in the perfused rat hearts used in the present study. Another possibility is that leukocytes and platelets interact and cooperate metabolically to facilitate transcellular biosynthesis of some mediator of inflammation, as is known to occur in the case of the leukotrienes. 25 Our results add to our knowledge of cell-to-cell interaction in the pathophysiology of reperfusion injury in several new ways. First, the interaction between PMNs and platelets is a synergistic one in which the response of the 2 cell types together is greater than that which would be predicted by the same numbers of the 2 cell types perfused separately. This synergism is clearly suggestive of a humoral interaction amplifying the actions of the 2 cell types, an effect that could be mediated, at least in part, by the selectin family of adhesion glycoproteins.
Second, we have provided evidence that blockade of the selectin family can markedly attenuate this synergism between platelets and neutrophils. This was demonstrable with an SLe X -OS, which blocks one of the major low-affinity ligands for the selectins, 26 and by a soluble PSGL-1, which blocks the major high-affinity ligand for P-selectin. 27 SLe X -OS agent has previously been reported to exert beneficial effects in myocardial ischemia-reperfusion in cats 9 and dogs, 28, 29 even up to 48 hours after reperfusion. These beneficial effects include reduced myocardial necrosis, fewer neutrophils infiltrating the heart, preserved coronary endothelial function, 9 better-maintained myocardial contractility, 9, 25 and enhanced coronary blood flow. 29 Similarly, sPSGL-1 has been shown to be effective in attenuating renal tissue injury in a rat model of renal ischemia-reperfusion. 22 These antiselectin agents could exert protective effects in one of several ways. Initially, these agents could have inhibited platelet P-selectinmediated effects between platelets and neutrophils or between platelets and endothelial cells. Alternatively, they could have inhibited endothelial P-selectin-mediated effects between endothelial cells and neutrophils. Probably, the overall protective effect of the antiselectin agents is a combination of all of these possibilities, because all 3 cell types are intimately involved in the pathophysiology of ischemia/ reperfusion. 30 Clearly, the adherence of PMNs to the endothelium is central to much of the ensuing pathophysiology, [7] [8] [9] whether it occurs as single PMNs or clusters of plateletneutrophil complexes.
The third major conclusion derived from these studies is that blood cells and mediators on their surface or released by these cells can induce significant effects on myocardial contractility in sensitized hearts (ie, I/R). Thus, in our model, myocardial ischemia/reperfusion in the absence of blood cells produced no deficit in cardiac contractility. When PMNs alone or platelets alone were added to the system, modest deficits in contractility occurred. PMNs isolated from the blood were comparable to elicited PMNs, indicating that partially activated PMNs contain sufficient mediators to produce significant cardiac dysfunction. Only when both cell types were given together at reperfusion was there a marked decline in coronary flow and cardiac contractility. Moreover, a comparable degree of cooperativity occurred between platelets and PMNs with ratios of 1.3:1 and 10:1. This suggests that the smaller numbers of circulating platelets are sufficient for this cooperativity between cell types. This could not be attributed to the mere presence of PMNs and platelets, because these cells together in nonischemic perfused rat hearts were without any effect on contractility or coronary flow. The dysfunction is indicative of an activation process that is dependent on reperfusion of an ischemic vasculature.
One may speculate as to the cellular mechanism of this PMN-platelet cooperativity in producing postreperfusion cardiac dysfunction. Several possibilities exist. First, PMN or platelet aggregates or PMN-platelet complexes could obstruct flow in significant numbers of coronary microvessels and plug up these vessels, thus interfering with the normal distribution of coronary flow to the cardiac myocytes. With regard to this possibility, we saw no evidence of obstruction in any of the histological sections we observed. However, we did observe small numbers of homotypic (ie, platelet-platelet or PMN-PMN) or heterotypic (ie, PMN-platelet) aggregates, but these were scattered and were not large enough to physically obstruct coronary vessels. There is evidence of this plugging up of vessels in vivo, 4 but under the conditions of our experiments, this did not occur. With regard to proinflammatory humoral mediators, both platelets and PMNs are rich in potential humoral candidates. Platelets have abundant prothrombotic and vasoconstrictor agents, including thrombin, histamine, thromboxane A 2 , and platelet factor 4. Several of these humoral agents could contribute to the reduced coronary flow observed in the present experiments, which could lead to cardiac contractile dysfunction. Many of these agents also upregulate P-selectin expression by translocation of P-selectin protein from ␣-granules to the surface of the platelet membrane. 31, 32 Moreover, neutrophils release a variety of cytokines, proteases, lipid mediators, and oxygenderived free radicals 30 -32 that can interact with plateletderived mediators. This combination of mediators could exacerbate both the reduced coronary flow and the cardiac contractile dysfunction observed in the present experiments. P-selectin expressed on platelet membranes could bind neutrophils to platelets and both cell types to the endothelium, which also expresses P-selectin on its surface translocated there from Weibel-Palade bodies. 32 We observed a significant increase in P-selectin expression on I/R coronary vascular endothelium in the presence of PMNs and platelets, and this was markedly attenuated by SLe X -OS. Under the conditions of the present flow-through experiment (ie, no recirculation), we could not accurately measure release of humoral agents, which could upregulate P-selectin. However, our results are consistent with the presence of humoral mediators. In any case, we have clear data to support the third hypothesis, that platelets and PMNs synergistically promote enhanced endothelial adhesivity and eventual transendothelial migration of PMNs into the I/R myocardium. We observed both significantly elevated cardiac MPO activity, a specific marker of neutrophils, and increased numbers of PMNs microscopically in ischemic hearts reperfused with both cell types compared with those reperfused with either cell type alone. The net result is to augment and exacerbate the effects of neutrophils on propagating cardiomyocyte injury after reperfusion of the ischemic myocardium. One factor contributing to this phenomenon could be the ability of activated PMNs to stimulate platelet function. 33 Therefore, these results suggest that either antiplatelet or antineutrophil agents may provide some benefit against reperfusion injury. Moreover, dual antiplatelet and antineutrophil therapy or an agent that addresses both cell types may be of particular utility in myocardial ischemia-reperfusion.
These findings are of potential clinical relevance but clearly must be confirmed in an in vivo model of reperfusion injury before further consideration of their implications can be addressed. Nevertheless, there are suggestions that these findings will be shown to be clinically relevant, 15, 19 as has been suggested in transplant rejection and stroke. 34 
